Asahi Quality and Innovations

Asahi Quality and Innovations (AQI) is the primary research and development subsidiary of Asahi Group Holdings, specializing in biotechnology, food science, and health-focused innovation. The company utilizes an extensive proprietary library of microorganisms, including yeast and lactic acid bacteria, to develop functional ingredients and postbiotics that target the gut-brain axis and immune system. AQI's research focuses on addressing societal health challenges such as stress, sleep quality, and cognitive decline through fermentation-based solutions. As the innovation engine for the Asahi Group, the company integrates advanced microbiome analysis with sustainable manufacturing processes to create value across the global beverage and food sectors. Their portfolio includes well-characterized strains like Lactobacillus gasseri CP2305, which are incorporated into commercial health products worldwide.